Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer

15 Mar 1990

Abstract excerpt

Intracellular thiols have been proposed as mediators of resistance to alkylating agents and cisplatin. As metallothionein is the predominant protein thiol, we examined its relationship to cisplatin resistance in human ovarian cancer cell lines. A human ovarian carcinoma cell line, A2780, derived from an untreated patient, was treated with cisplatin in several ways and the induced resistance to cisplatin ranged...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Iron Metabolism and Disorders
Share to Trace Elements in Health

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 2307530
DOI: 10.1002/ijc.2910450306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metallothionein gene expression and resistance to cisplatin in human ovarian cancerPMID 2307530Read ↗

Cisplatin resistance and oncogenes - a reviewSemantic proximity Read ↗

BCL-2 family protein expression and platinum drug resistance in ovarian carcinomaSemantic proximity Read ↗

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.Semantic proximity Read ↗

Development of resistance to a trinuclear platinum complex in ovarian carcinoma cellsSemantic proximity Read ↗

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell linesSemantic proximity Read ↗

Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.Semantic proximity Read ↗

ras mutation and platinum resistance in human ovarian carcinomas in vitro.Semantic proximity Read ↗

Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell linesSemantic proximity Read ↗

Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivoSemantic proximity Read ↗

Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failureSemantic proximity Read ↗

Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.Semantic proximity Read ↗

Molecular analysis of DNA damage induced by a novel trinuclear platinum complex (BBR 3464)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.